Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Giant-Cell Arteritis Market?

The market size of giant-cell arteritis has seen a powerful growth recently. It’s projected to expand from $1.07 billion in 2024 to $1.12 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.0%. The growth during the past period can be credited to factors such as epidemiological research, genetic advancements, the increasing use of biologics, enhancement in diagnostic methods, and the progression of targeted therapies and biologics.

In the coming years, the market size of giant-cell arteritis is anticipated to sustain a steady growth. It is predicted to inflate to $1.34 billion in 2029, with a 4.6% compound annual growth rate (CAGR). Factors contributing to the growth during the forecast period include improved diagnosis rates, an aging demographic, enhanced healthcare spending, active patient advocacy, and extending into new geographical areas. The forecast period is also expected to see key trends such as enhancement in the identification and validation of biomarkers, the advent of therapies targeting distinctive molecular pathways, adoption of sophisticated imaging methods, innovations in drug delivery, and the application of AI algorithms for predictive analysis.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

What Are The Primary Factors Supporting The Giant-Cell Arteritis Market Expansion?

The surge in personalized medicine is seen as a significant factor propelling the expansion of the giant-cell arteritis market. The concept of personalized medicine ensures medical treatments are tailored according to individual characteristics, such as genetic makeup, lifestyle, and environment. The growth of personalized medicine is fueled by advancements in genomics, biotechnology, and data analytics, which facilitate targeted therapies enhancing treatment effectiveness and reducing negative impacts. In the case of giant-cell arteritis (GCA), providing personalized treatments based on factors like genetic predispositions, immune profiles, and disease expressions can be beneficial. The Personalized Medicine Coalition (PMC), an American non-profit organization, reported in February 2024 that personalized medicines made up more than one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for four consecutive years, up to 2023. During 2023, the FDA endorsed 16 new custom-tailored treatments for rare diseases, an upturn from six approvals in 2022. Seven cancer medicines and three therapies for various other diseases were among the approved treatments in 2023. Hence, the escalating focus on personalized medicine is instrumental in driving the evolution of the giant-cell arteritis market.

Which Segments Define The Structure Of The Giant-Cell Arteritis Market?

The giant-cell arteritismarket covered in this report is segmented –

1) By Therapeutics: Prednisone; Methotrexate; Tocilizumab; Aspirin

2) By Mechanism Of Action: Corticosteroids; Immunosuppressive Agents; Anticoagulants; Other Mechanisms Of Action

3) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone; Intravenous (IV) Prednisone; Low-Dose Prednisone Therapy; High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate; Subcutaneous Methotrexate; Methotrexate Monotherapy; Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab; Subcutaneous Tocilizumab; Tocilizumab Monotherapy; Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy; Aspirin For Cardiovascular Risk Management; Aspirin In Combination Therapy; Enteric-Coated Aspirin

What Strategic Shifts And Innovations Are Influencing The Giant-Cell Arteritis Market?

Leading businesses in the field of giant-cell arteritis are innovating and releasing new offerings like biosimilars to broaden therapeutic avenues and fulfill the unaddressed medical needs of their patients. Biosimilars are biologic medicines that closely mirror already approved biological medications, possessing no significant clinical disparities in safety, purity, and effectiveness. For example, in April 2024, Fresenius SE & Co. KGaA, a health care company based in Germany, introduced Tocilizumab-aazg in the US, targeting chronic autoimmune diseases. This biosimilar is greenlit for ailments including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. The approval was granted based on results from a phase 1 trial where it was randomized, double-blind, single-dose, and parallel to compare its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient demographics.

Who Are The Primary Market Leaders In The Giant-Cell Arteritis Market?

Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

What Regional Factors Are Accelerating Growth In The Giant-Cell Arteritis Market?

North America was the largest region in the giant-cell arteritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2025, By The Business Research Company

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Stem Cell Cord Blood Banking Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

Induced Pluripotent Stem Cell Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model